drugset / Trial / NCT00651235
A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
RandomizedFactorialOpen-labelPrevention
Summary
To assess the efficacy of angiotensin II receptor blocker, Losartan, to prevent progressive dilation of aortic root in patients with Marfan syndrome.
Timeline
- Start
- 2007-02
- Primary completion
- 2011-02
- Completion
- 2011-06
Outcome
Met primary endpoint
paper annual dilation rate of the aortic root was significantly lower than that of the BB group (0.10 mm/yr vs 0.89 mm/yr; P=.02). PMID 23321647 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 50 mg | — |
| Subject | Losartan | Other / unclassified | 100 mg | — |
| Comparator | Atenolol | Other / unclassified | 2 mg/kg | — |
| Comparator | Atenolol | Other / unclassified | 50 mg | — |
| Comparator | Atenolol | Other / unclassified | 150 mg | — |
| Comparator | Propranolol | Small molecule | 1 mg/kg | — |
| Comparator | Propranolol | Small molecule | 2 mg/kg | — |
| Comparator | Propranolol | Small molecule | 20 mg | — |
| Comparator | Propranolol | Small molecule | 150 mg | — |